UniQure stock tumbles on FDA comments about gene therapy trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
RBC Capita on uniQure BV (QURE): 'The Commissioner's comments are clearly disappointing'
February 26, 2026 2:28 PM ESTRBC Capital analyst Luca Issi reiterated an Outperform rating and $45.00 price target on uniQure BV (NASDAQ: QURE).
The analyst comments "Our take: The Commissioner's comments are clearly disappointing as the Agency appears less open-minded on a path forward for HD. We do find the commentary somewhat... More
